NRSN
NASDAQNeuroSense Therapeutics Ltd.
Price$0.78-0.10 (-10.95%)
01:45 PM07:45 PM
News · 26 weeks48+100%
2025-12-282026-06-21
Mix2590d
- Insider9(36%)
- Other8(32%)
- SEC Filings8(32%)
Latest news
25 items- PREverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the DotsCAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that EverythingALS will host a conversation built around a look at emerging data on PrimeC and what it may mean for the science of ALS and the people living with it. Event details:Date: June 24, 2026Time: 7 pm ETLink for registration: Click HereThe session will be presented by Prof. Jeffrey Rosenfeld, MD, PhD, FAAN, Professor of Neurology and Director of the Neuromuscular ALS/MND Program at Loma Linda University School of Medicine. With more than
- INSIDERChief Executive Officer Ben-Noon Alon bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 6% to 4,534,233 units (SEC Form 4)4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- INSIDERChief Financial Officer Eisenberg Or bought $200,000 worth of Ordinary Shares (250,000 units at $0.80), increasing direct ownership by 20% to 1,504,050 units (SEC Form 4)4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- PRNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALSPatent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALSExpands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in Japan, Brazil, Australia and the United StatesFurther strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeCCAMBRIDGE, Mass., June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued Korean
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- PRNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel CompositionPatent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The patent, entitled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- PRNeuroSense Announces Pricing of Insider-Led PIPE FinancingFinancing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholderCAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with certain investors to purchase $600,000 of ordinary shares in a private placement. In connection with the offering, NeuroSense agreed to sell an aggregate of 750,000 ordinary shares at a price of $0.80 per share, representing a purchase price of 6.7% above the closing pricing of NeuroSense's ordinary
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- PRNeuroSense Granted Brazilian Patent Covering PrimeC CompositionPatent Protection Through October 2042Follows prior patent grants in the U.S. and AustraliaFurther strengthens NeuroSense's global intellectual property portfolioCAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled "Compositions Comprising Ciprofloxacin and Celecoxib." The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian
- PRNeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsNotifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026 to regain compliance with both requirementsThe Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder valueCAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today announced that it received two notification letters from the Listing Qualifications Department of
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- INSIDERSEC Form 4 filed by Eisenberg Or4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- INSIDERSEC Form 3 filed by new insider Eisenberg Or3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mandil-Levin Revital3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- SECSEC Form 6-K filed by NeuroSense Therapeutics Ltd.6-K - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- SECSEC Form 20-F filed by NeuroSense Therapeutics Ltd.20-F - NeuroSense Therapeutics Ltd. (0001875091) (Filer)
- PRNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALSStatistically significant survival benefit demonstrated, including 65% reduction in risk of death and >14-month median survival advantageResults published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activityAdvancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readoutCAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative disea
- INSIDERSEC Form 3 filed by new insider Russek-Blum Niva3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- INSIDERSEC Form 4 filed by Russek-Blum Niva4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ben-Noon Alon3 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
- INSIDERSEC Form 4 filed by Binder Hagit4 - NeuroSense Therapeutics Ltd. (0001875091) (Issuer)
NRSN FAQ
6 questionsWhere does NRSN stock trade?
NeuroSense Therapeutics Ltd. (NRSN) is listed on NASDAQ.What sector and industry is NRSN in?
NeuroSense Therapeutics Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NeuroSense Therapeutics Ltd. go public?
NeuroSense Therapeutics Ltd. (NRSN) completed its IPO in 2021.What are analysts saying about NRSN?
NeuroSense Therapeutics Ltd. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $700.00 price target on 2022-01-07. Recent price targets cluster around $700.00.What companies are similar to NRSN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NRSN side-by-side with any of them on Quantisnow.How can I track NRSN on Quantisnow?
Quantisnow aggregates NeuroSense Therapeutics Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRSN to receive live email and push alerts on every new disclosure.